PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced results of new clinical research of its Immuno-Oncology agents – Opdivo andYervoy – will be presented at the Society for Melanoma Research (SMR) 2015 International Congress in San Francisco, CA from November 18 – 21. Studies to be presented at SMR illustrate Bristol-Myers Squibb’s scientific commitment, through its Immuno-Oncology research, to developing treatment options for patients with advanced melanoma.
Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination with Yervoy (ipilimumab), at the Society for Melanoma Research 2015 International Congress | BMS Newsroom
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.